David Shaw’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,728,102
| Closed | -$2.54M | – | 5780 |
|
|
2022
Q2 | $2.54M | Sell |
1,728,102
-592,596
| -26% | -$435K | ﹤0.01% | 2853 |
|
|
2022
Q1 | $2.67M | Buy |
2,320,698
+2,061,176
| +794% | +$3.36M | ﹤0.01% | 3018 |
|
|
2021
Q4 | $649K | Buy |
+259,522
| New | +$1.02M | ﹤0.01% | 4248 |
|
|
2021
Q2 | – | Sell |
-44,130
| Closed | -$384K | – | 5137 |
|
|
2021
Q1 | $384K | Sell |
44,130
-51,608
| -54% | -$534K | ﹤0.01% | 3619 |
|
|
2020
Q4 | $1.04M | Buy |
95,738
+55,632
| +139% | +$686K | ﹤0.01% | 2999 |
|
|
2020
Q3 | $478K | Buy |
+40,106
| New | +$537K | ﹤0.01% | 3251 |
|
|
2020
Q2 | – | Sell |
-11,124
| Closed | -$173K | – | 4326 |
|
|
2020
Q1 | $173K | Sell |
11,124
-177,300
| -94% | -$3.81M | ﹤0.01% | 3685 |
|
|
2019
Q4 | $4.63M | Buy |
+188,424
| New | +$2.8M | 0.01% | 1796 |
|
|
2019
Q3 | – | Sell |
-13,261
| Closed | -$166K | – | 4090 |
|
|
2019
Q2 | $166K | Sell |
13,261
-148,350
| -92% | -$1.91M | ﹤0.01% | 3498 |
|
|
2019
Q1 | $2M | Buy |
+161,611
| New | +$1.81M | ﹤0.01% | 2156 |
|
|
2017
Q2 | – | Sell |
-50,577
| Closed | -$867K | – | 3600 |
|
|
2017
Q1 | $867K | Buy |
+50,577
| New | +$674K | ﹤0.01% | 2395 |
|
|
2014
Q3 | – | Sell |
-21,900
| Closed | -$682K | – | 4472 |
|
|
2014
Q2 | $682K | Buy |
+21,900
| New | +$516K | ﹤0.01% | 3265 |
|
Other funds holding EPZM
David Shaw's EPZM Position: Q3 2022 in Review
David Shaw sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 1,728,102 shares — an estimated $2.54M sold.
David Shaw first reported a position in EPZM in Q2 2014 and held it in 12 quarters. The position peaked at $4.63M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- David Shaw reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- David Shaw sold 1,728,102 Epizyme, Inc shares in Q3 2022, an estimated $2.54M.
- David Shaw first reported a position in Epizyme, Inc in Q2 2014 and held it in 12 quarters.
- David Shaw's Epizyme, Inc position peaked at $4.63M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.